STATISTICAL ISSUES IN META-ANALYSIS FOR IDENTIFYING SIGNATURE GENES IN THE INTEGRATION OF MULTIPLE GENOMIC STUDIES by Li, Jia
STATISTICAL ISSUES IN META-ANALYSIS FOR
IDENTIFYING SIGNATURE GENES IN THE




BS, Dongbei University of Finance and Economics, China, 2001
MS, The University of Alabama, 2004
Submitted to the Graduate Faculty of
the Department of Biostatistics
Graduate School of Public Health in partial fulfillment






GRADUATE SCHOOL OF PUBLIC HEALTH
This dissertation was presented
by
Jia Li




George C. Tseng, ScD
Assistant Professor
Department of Biostatistics
Department of Human Genetics


















Graduate School of Public Health
University of Pittsburgh
ii
Copyright c© by Jia Li
2008
iii
STATISTICAL ISSUES IN META-ANALYSIS FOR IDENTIFYING
SIGNATURE GENES IN THE INTEGRATION OF MULTIPLE GENOMIC
STUDIES
Jia Li, PhD
University of Pittsburgh, 2008
With the availability of tons of expression profiles, the need for meta-analyses to integrate
different types of microarray data are obvious. For detection of differentially expressed genes,
most of the current efforts are focused on comparing and evaluating gene lists obtained from
each individual dataset. Several statistical meta-analysis methods, including Fisher’s method
and the random effects model, have been proposed but the statistcal framework is not often
rigorously formulated for evaluation and comparison. In this dissertation, we attempt to
formulate meta-analysis in genomic studies and develop systematic integration methods for
two-class studies and multi-class studies.
First, we tackle two often-asked biological questions:“Which genes are significant in one
or more data sets?” and “Which genes are significant in all data sets?”. We illustrate two
statistical hypothesis settings and propose an optimally weighted statistic and compare to
classical Fisher’s equally weighted statistic and Tippett’s minimum p-value statistic. Gener-
ally there exists no uniformly most powerful test and we show that all of the three methods
are admissible under simplified Gaussian assumptions. Furthermore, the optimally weighted
statistic maintains advantages of the two classical methods and consistently performs well
when the two methods perform poorly in respective extreme alternative hypotheses. The
optimal weights provide natural categorization of the detected genes to facilitate further bi-
ological investigation. We demonstrate the comparison and advantages of optimally weighted
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statistic by power analysis, simulations and two real data analyses of combining multi-tissue
energy metabolism mouse data sets and prostate cancer data sets.
Second, we propose two methods for identifying biomarkers of concordant patterns across
studies, when there are more than two classes in each study. So far, published meta-analysis
methods for this purpose mostly consider two-class comparison. Methods for combining
multi-class studies and pattern concordance are rarely explored. We first consider a natural
extension of combining p-values from the traditional ANOVA model. Since p-values from
ANOVA do not reflect pattern information, we propose a multi-class correlation measure
(MCC) under equal-weight bivariate mixture model to specifically seek for biomarkers of
concordant patterns across a pair of studies. For both approaches, we focus to identify
biomarkers differentially expressed in all studies (ANOVA-maxP, min-MCC). Both ANOVA-
maxP and min-MCC are evaluated by simulation studies and by applications to a multi-tissue
mouse metabolism data set and a multi-platform mouse trauma data set.
Finally, we develop a “genomeMeta” R package. genomeMeta produces visualization
and summarization of biomarkers identified by methods that we describe and propose in this
dissertation.
This work could improve public health by providing more effective methodologies for
biomarker detection in the integration of multiple genomic studies.
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1.0 INTRODUCTION
In this introductory chapter we start in section 1.1 by describing the data structure of
microarray data particulary in the context of multiple microarray data sets. We further
describe an example to help you understand the data structure. In section 1.2, we use this
example to illustrate the idea of meta-analysis methods.
1.1 MICROARRAY DATA STRUCTURE AND AN EXAMPLE
Microarray technology allows researchers to examine the expression of thousands of genes
in parallel. With microarray experiments becoming more and more mature and prevalent,
the integration of experimental data sets from multiple laboratories and experimental tech-
niques has become one of the most challenging tasks in bioinformatic and genomic research.
In contrast to traditional epidemiological or psychological studies, microarrays monitor gene
expression for thousands of genes simultaneously - a process that brings challenges to inte-
grative analysis. The standard data structure for a set of microarray studies used in this
dissertation is provided here.
Let ygsk denote the gene expression for the gth gene in the sth sample of the kth study,
g = 1, . . . , G, s = 1, . . . , Sk, k = 1, . . . , K. Sample annotations are denoted as rsk, where in
any given study k, common microarray designs can include (1) rsk ∈ {0, 1} (two-class com-
parison); (2) rsk ∈ {1, 2, . . . , J} (multi-class comparison); (3) rsk = (tsk, csk) (tsk: survival
time; csk: censoring status); (4) rsk ∈ R (time series). Given study k, suppose an appropriate
test statistic Tk is chosen for the data structure {rsk; 1 ≤ s ≤ Sk} and the resulting p-values
for each gene g (denoted as pgk) can be derived from the observed expression intensities
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Table 1: An example.
Tissue type (k) Brown fat Liver Heart Skeletal totalGenotype1 (rsk) 1 2 3 1 2 3 1 2 3 1 2 3
Number of arrays 4 4 4 4 4 4 3 4 4 3 3 3 44
a1: Wild type; 2: VLCAD -/-; 3: LCAD -/-.
{ygsk, 1 ≤ s ≤ Sk}.
Example: The below example of integrative analysis of microarray studies is the multi-
tissue analysis on variability in gene expression profiles across four tissues (heart, skeletal
muscle, liver, and brown fat) as a consequence of single enzyme deficiency in the mitochondrial-
oxidation pathway. Using VLCAD-deficient (VLCAD-/-), LCAD-deficient (LCAD-/-), and
wild type (VLCAD+/+, LCAD+/+) mouse models, we apply whole genome microarray
methods to investigate tissue dependent responses to single defects in these mitochondrial-
oxidation enzymes. Thus, in this example, each study represents a tissue (K = 4). Three to
four individuals are sampled per genotype and tissues, accounting for 45 samples in total.
One out of the 45 hybridizations (wild type heart sample) have to be excluded due to detected
significant degradation of RNA (Table 1), and 14495 genes are investigated (G = 14495).
VLCAD is involved in degradation of long- and very long-chain unsaturated substrates from
C14 to C20, with optimum for palmitoyl-CoA (C16:0-CoA). It is ubiquitously expressed in
human tissues with high levels in liver, heart, and skeletal muscle. To compare the variation
in gene expressions between wild type and VLCAD-/-, we can set rsk ∈ {1, 2} and analyze
a total of 29 samples. To investigate gene variation in wild type, VLCAD-/- and LCAD-/-,
we can set rsk ∈ {1, 2, 3} analyze the entire 44 samples.
1.2 META-ANALYSIS
As the global expression analysis by microarray technology becomes more and more preva-
lent, systematic information integration of multiple genomic studies brings new statistical
challenges. The challenge to statisticians is to develop effective methodologies for combining
information from related studies. This type of analysis is often called meta-analysis.
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The main aim of meta-analysis is first, to provide a more powerful statistical test of a spe-
cific study hypothesis than a test provided by each study separately, and second, to provide
validation for findings from the individual study. Meta-analysis has a long history, which
have been widely used in epidemiology and evidence-based medicine ever since early twenties.
Meta-analysis methods can be categorized into two traditions. One is to combine statistical
significance from each individual study, and the other is to combine statistical estimates par-
ticularly effect sizes from each individual study. The representative methodologies for the
first tradition are Fisher’s method (Fisher, 1932), Tippett’s minimum p-value (Tippett,1931)
and Wilkinson’s maximum p-value (Wilkson, 1951). The representative methodologies for
the second tradition are fixed and random effects models. Details of traditional methodolo-
gies are described in section 1 of chapter 2. There are advantages and disadvantages for both
of the traditions. Briefly, methods based on combining significance are free of distributional
assumptions, but do not support inferences about magnitudes and directions. On the other
hand, methods based on combining estimates provide information about magnitudes and
directions, but are more stringent on assumptions. And they can not be easily extended to
more complicated studies such as studies with multiple classes.
With microarray experiments becoming more mature and more prevalent, the integration
of experimental data sets from multiple laboratories and experimental techniques has become
one of the most challenging tasks in bioinformatic and genomic research. Currently “meta-
analysis” in the biological literature contains a widespread use of naive “intersection” and/or
“union” operations on differentially expressed gene lists obtained from individual studies by
certain criteria (e.g. False Discovery Rate ≤ 0.05) (Segal et al., 2004, Borovecki et al., 2005,
Cardoso et al., 2007, Pirooznia et al., 2007, and many more). One can quickly note that
intersections are often too conservative and unions are anti-conservative, especially when the
number of studies increases. For instance, Table 2 lists two-sample moderated t statistics,
several often used meta-analysis methods and corresponding p-values for comparison between
wild type and VLCAD-/- in each tissue for several genes in the mouse energy metabolism
example in section 1.1. For the purpose of illustration, we do not worry about multiple
comparisons in this example. Using the intersection method, individual p-values ≤ 0.05 in
all tissues, is too conservative and all of the top three genes listed in table 2 are not identified.
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Table 2: Several examples for meta analysis methods.
P-values of moderated t statistic statistics(p-values) for meta analysis methods
Brown fat Liver Heart Skeletal Fisher minP maxP REM
1417025 at 0.636 0.008 0.001 0.024 16.56(7E-06) 0.001(0.002) 0.636(0.181) -0.056(0.952)
1424039 at 0.006 0.005 0.005 0.526 16.56(7E-06) 0.005(0.018) 0.526(0.092) -1.953(0.051)
1415994 at 0.668 0.815 0.694 0.002 7.32(0.007) 0.002(0.007) 0.815(0.453) -0.431(0.666)
1416531 at 0.001 0.008 0.008 0.005 21.69(1E-05) 0.001(0.005) 0.008(1E-20) 4.978(6E-07)
Note: P-values are obtained by permutation analysis.
Fisher: Fisher’s method; minP: Tippett’s minimum p-value method; maxP: Wilkinson’s maximum
p-value; REM: random effects model.
Several research groups have developed statistical methodologies particularly for microar-
ray studies based on traditional meta-analysis methods. They are discussed in section 2 of
chapter 2. For example, Fisher’s method and the random effects model are widely used.
Multiple comparisons also need to be addressed in genomic studies. The statistical frame-
work, however, is often not rigorously formulated and a formal evaluation and comparison
could not be performed. According to the individual analysis in table 2, we note that genes
behave differently across tissues, because it is expected that tissue specific physiology will
result in tissue dependent responses. From table 2, gene 1416531 at which has small p-values
in four tissues is identified by all methods while the others genes which have small p-values
in some, but not all of the tissues are identified by Fisher’s method and Tippett’s minimum
p-value method. Thus, we can say that maxP and the random effects model tend to detect
genes differentially expressed between wild type and VLCAD-/- in all tissues, while minP
and Fisher’s methods detect genes differentially expressed between wild type and VLCAD-
/- in at least one of the tissues. A statistical framework should be rigorously defined for
different methodologies. In the first part of chapter 3, two complementary hypothesis set-
tings are outlined. And all meta-analysis methods targeted for their respective hypothesis
settings are clarified. If tissue specific genes are of greater interest and we would like to
know in which tissue the gene is differentially expressed, more powerful methodologies such
as the optimally-weighted statistic (OW) can be developed. The details are discussed in the
remaining part of chapter 3.
Returning to the example in section 1.1, if one would like to investigate the variation
in gene expression among wild type, VLCAD-/- and LCAD-/-, there are three classes to
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be compared in each issue. As a natural extension, an ANOVA model can be used to
test the significance of variation in gene expressions across genotypes in each tissue. The
corresponding p-values from F-test are then combined using different methods. In addition,
genes demonstrating a consistent pattern across the four tissues might be of greater interest
to investigators. So far, however, most of the methods in the literature, including those
described above, focus on the two group comparison. Combining data sets with more than
two groups is rarely discussed. Here, we propose a minimum multi-class correlation statistic
(minMCC) to address this problem. The simulation studies and the application to the mouse
energy metabolism data and mouse trauma data indicate that minMCC is a powerful test for
identifying biologically relevant expression changes. The methods are described in chapter
4.
Chapter 5 describes an R package -genomeMeta that we developed for the visualization
and implication of all possible meta-analysis methods for microarray data. We discuss how
to use the package in several examples. This is followed by a conclusion and discussion in
Chapter 6.
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2.0 PREVIOUS META-ANALYSIS METHODS
2.1 META-ANALYSIS METHODS IN TRADITIONAL EPIDEMIOLOGIC
RESEARCHES
In this section we consider K independent experiments that have been performed to detect a
certain effect. Here θk is the parameter that characterizes the effect of study k, k = 1, . . . , K.
The kth experiment is designed to test the hypothesis H0k : θk = 0 against an alternative
H1k : θk 6= 0 using the test statistic Tk. Significance levels and effect sizes are two common
metrics utilized in meta-analysis. In the following, we introduce several methods for each
metric separately.
2.1.1 Methods for combining significance
The methods of combining significance of independent tests have been discussed by a number
of researchers, including Fisher (1932) and Pearson (1938). Assuming Tk follows a continuous
distribution, the significance of a test is often defined as pk = Pr(Tk > tk|H0k), that is, as
a p-value. Note that when H0k is true, pk is uniformly distributed. Thus, combining the
significance of independent tests is sometimes called omnibus or nonparametric.
2.1.1.1 Fisher’s Method The best known method in this category is Fisher’s (1932).
Fisher’s method uses the product of p-values from the test for each experiment and trans-
forms it to chi-square scores using a −2log transformation resulting in





For this reason it is also known as the Inverse Chi-square method. If all of the null hypotheses
of the K tests are true, then −
K∑
k=1
2log(pk) will have a χ
2 distribution with 2K degrees of
freedom.
Fisher’s method was shown in the literature to have good power under a wide range of
alternative conditions and to be the most asymptotically Bahadur optimal (ABO) among
several commonly used combined tests (Little and Folks, 1971, 1973). Fisher’s method, how-
ever, is easily been dominated by small p-values because of its asymmetric transformation.
For example, for gene 1415994 at in table 2, one of these tissues rejects the null hypothesis
with p = 0.002, while the others do not. By Fisher’s method the p-value is 0.007, and we still
say the gene is differentially expressed. Another drawback of the Fisher’s method can be seen
from the examples, genes 1417025 at and 1424039 at clearly behave differently across tissues,
but the same results are obtained by Fisher’s method (V EW = 16.56, p− value = 7E − 06).
To distinguish between these two genes, an ad-hoc approach has to be added.
2.1.1.2 The Truncated Product Method Zaykin et al. (2002) of proposed a trun-
cated version of Fisher’s method, where they suggest using the product of p-values that do
not exceed a value τ :






where I(·) is the indicator function. This test is less sensitive to small p-values, however,
the choice of τ is arbitrary (the authors suggest a conventional value such as 0.05).
2.1.1.3 Tippett’s Minimum p Method This method is proposed by Tippett (1931),
where
V minP = min
1≤k≤K
pk. (2.3)
Therefore, H0 is rejected if min1≤k≤K pk ≤ 1− (1−α)1/K , where α is the overall significance
level, because min1≤k≤K pk has a Beta(1, K) distribution under the null hypothesis.
NOTE: This method is also known as the union-intersection method. If the rejection
region for the test of H0k is {pk ≤ α}, then the rejection region for the union-intersection
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test for H0 : θ ∈
⋂K




k=1{pk ≤ α}, which is exactly the same
as {min1≤k≤K pk ≤ α}.
Like Fisher’s test, this method is sensitive to small p values, but it is less powerful than
Fisher’s approach especially when all studies are significant. Again in table 2, p-values from
the four tissues of gene 1415994 at are 0.668,0.815,0.694 and 0.002 respectively. By the
minimum p method, the p-value of V minP is 0.007. If the p-value of skeletal is changed to
0.02, the p-value of V minP becomes 0.08. The conclusion is to fail to reject H0.
2.1.1.4 Wilkinson’s Method Wilkinson (1951) generalized Tippett’s procedure to a
more robust rth smallest p-value giving
V W = p(r). (2.4)
The maximum p-value is a special case and the most frequently used. It is often referred to
as Wilkinson’s method.
V maxP = max
1≤k≤K
pk. (2.5)
It is worth noting that the maximum P-value statistic is a special case of the intersection-
union test (Berger, 1982). According to Berger’s theorem for intersection-union test (IUT),
the intersected region for H0 : θ ∈
⋃K
k=1Θk vs. H1 : θ ∈
⋂K
k=1Θk is Rg =
⋂K
k=1
leqα} = {max1≤k≤K pk ≤ α}.
2.1.1.5 Other Transformations As noted above, Fisher’s method utilizes an inverse
Chi-square transformation. Some other transformations have been considered in the litera-







This statistic is asymptotically standard normal distribution when the H0k are all true.
The inverse Normal transformation test takes advantage of the one-to-one mapping of the
symmetric standard normal curve to the p-values. Thus it treats large and small p-values
symmetrically.
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Another method worth noting is the Logit transformation suggested by George (1977).






1− pk . (2.7)
The distribution of V L can be easily derived. George and Mudholkar (1977) show that
it can be approximated by a t distribution with 5K + 4 degrees of freedom.
2.1.1.6 The Weighted Method One of the limitations of the above methods is that
they do not weight evidence from the studies according to their uncertainties or sample
sizes. Different weights and variants to existing methods have been considered. Good (1955)





if the weights are all unequal. The probability density function of −logV G is∑Kk=1 Wkwk e−v/wk
where Wk = w
K−1
k /((wk − w1)(wk − w2) . . . (wk − wk+1)(wk − wK)).
Zelen and Joel (1959) provide a detailed investigation of the weighted version when K is
2 and
∑
wk = 1, where the test is from an F test for variance ratios. They also discuss the
effect of the weight factor on the type II error of the combined test. However, it is clear that
the distribution is not easily calculated in general cases. In addition, in practice, it is hard
to determine the weights and it is unrealistic that all weights are unequal. So the method is
seldom used in practice.
Another weighted method seen in the literature is the weighted inverse Normal transfor-







Whitlock (2005) suggests that the weights can be chosen to be the inverse of squared standard
error. He further shows that the weighted method is superior to the unweighted version.
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Table 3: Different indexes of effect magnitude have been
used in meta-analysis
















Log risk ratio log(P1
P2
)
Log odds ratio log[P1(1−P2)
P2(1−P1) ]
y1 and y2 are the means for the group 1 and 2 respectively;
s1 and s2 are the standard deviations of group 1 and 2 respec-
tively;
P1 and P2 are the proportion of subjects in group 1 and 2
respectively.
2.1.2 Methods for combining estimates
When the studies have similar designs and measure the outcome in a similar manner, combin-
ing estimates is usually preferred to the omnibus methods in previous section as suggested
by some researchers. Suppose Tk, k = 1, . . . , K are the independent estimates of effect
magnitude from K studies. The corresponding population effect magnitude parameters are
θk, k = 1, . . . , K. There are many different metrics that can be used to measure effect size.
They are listed in table 3. Of these, Cohen’s d is used most often and it can be transformed
from Pearson’s r and Hedges’s g. Note that all of the measurements focus on two group com-
parisons, effect size for more than two groups may not be easily defined. The distribution of
effect estimates for more than two groups in large sample cases also presents difficulties.
The statistical analysis procedures of combining estimates all involve large-sample theory.
There are three major types of statistical analysis for combining estimates: fixed, random
and mixed effects models. In the following sections, we focus on two most commonly used
models: fixed and random effects models (Hedges and Vevea, 1998).
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2.1.2.1 Fixed effects model Fixed effects models consider only within-study variabil-
ity. The assumption is that studies use identical methods, samples, and measurements;
that they should produce identical results; and that differences are only due to within-study
variation. The general model is given by
Tk = θk + ²k, ²k ∼ N(0, σ2k). (2.10)
In the fixed effects model, we assume there is a constant effect size µ for all studies, θ1 =
θ2 = . . . = θK = µ. Thus, Tk ∼ N(µ, σ2k). The most efficient and unbiased estimator of µ
is the weighted average of the estimates where the weights are determined by the inverse of















A test statistic can be constructed to test the hypothesis that θ1 = . . . = θK = µ = 0 as
follows: Z = µˆ√
V ar(µˆ)
, which follows the standard normal distribution, when
∑K
k=1 nk →∞
where nk, k = 1, . . . , K are the sample sizes of K studies.
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2.1.2.2 Random effects model An alternative approach, the random effects model,
allows the study outcomes to vary accordingly to a normal distribution between studies.
Many investigators consider the random effects approach to be a more natural choice than
fixed effects models. The random effects model is defined as
Tk = θk + ²k, ²k ∼ N(0, σ2k)
θk = µ+ δk, δk ∼ N(0, τ 2). (2.13)
That is, the true study effect size θk is no longer a constant effect, it varies across studies
with mean µ and variance τ 2. Obviously, the fixed effects model is a special case of the
random effects model when one assumes τ 2 to be 0.






where Wk = 1/(S
2
k(Tk) + τˆ
2). That is the variation comes from two sources: within study
variation, S2k(Tk), and between study variation, τ
2. There are several ways of estimating
τ 2. DerSimonian & Laird (1986)’s method is among the most commonly used approach to
estimate τ 2 by the method of moments. The estimate is given by
τˆ 2 = max[0,












Some more complex procedures for estimating τ 2 are given by Rubin (1980,1981), Rau-
denbush and Bryk (1985), and Hedges and Olkin (1985).
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2.1.2.3 Choosing between fixed and random effects models As noted above, the
random effects model may be more general, since both the random variation within the
studies and the variation between the different studies is incorporated. However, more data
are required for random effects models to achieve the same statistical power as fixed effects
models. Testing how much heterogeneity there is serves as a way to determine whether fixed
effects model is appropriate. Heterogeneity in meta-analysis refers to the variation in study
outcomes between studies.
There are three general ways to assess heterogeneity in meta-analysis, but each has
a liability for interpretation. First, one can assess the between-studies variance, τ 2, but
its values depend on the particular effect size metric used, along with other factors. The
second is Cochran’s Q, where Q =
∑K
k=1Wk(Tk − µˆ), which is the weighted sum of squared
differences between individual study effects and the pooled effect across studies. Under the
null hypothesis of homogeneity, Q is distributed as a chi-square statistic with K − 1 degrees
of freedom. A large Q indicates possible heterogeneity in the studies and that the fixed
effects model may not be valid. However, the Q test only informs meta-analysts about
the presence versus the absence of heterogeneity, but it does not report on the extent of
such heterogeneity. The third approach is the I2 index (Higgins and Thompson, 2002). It
quantifies the degree of heterogeneity in a meta-analysis. I2 = 100%(Q − (K − 1))/Q, if
Q > K − 1, otherwise, I2 = 0. So unlike Q, it does not inherently depend upon the number
of studies considered. It is interpreted as a percentage of heterogeneity. A confidence interval
for I2 is also constructed by Higgins and Thompson (2002).
2.2 META-ANALYSIS METHODS FOR MICROARRAY STUDIES
Most meta-analytic methods for microarray studies are based on extensions of the established
methods used for traditional epidemiological research. For example, Rhode et al. (2002) is
among the first to apply Fisher’s method to microarray data. Choi et al. (2003) implement
random effects models and Gentleman et al. (2008) developed a R package GeneMeta for
the methods Choi et al. described. We demonstrate several methods in the following using
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the same notation described in chapter 1; let ygsk denote the gene expression for the gth
gene in the sth sample of the kth study.
In addition to Fisher’s method, the same group of Rhode provided three algorithms for
the analysis of prostate cancer datasets (Ghosh et al., 2002). In the first algorithm, they use
the least absolute shrinkage and selection operator (LASSO; Tibshirani, 1996). LASSO is a
variable selection method for linear regression. It minimizes sum of squared errors subject





(Ygsk − µg)2 (2.16)
subject to the constraint that
∑G
g=1 |µg| ≤ λ. A gene is considered a candidate gene if
the estimate of µg is not zero, where µg denotes the mean normalized difference in gene
expression between the two groups (e.g. Tumor and Normal). Estimating λ is challenge in
microarray analysis. The cross-validation technique is not appropriate here because of the
dependence structure of genes. One could generate different gene lists for a list of different
values of λ. In their second algorithm, they calculated a weighted sum of t statistics across
studies for each gene, with the weights being the ratio of sample size of the individual study







Weighting each study according to the sample size is intuitive yet arbitrary. And last, they
provide a more general model by taking into account the interaction between study and
tissue types through the following model:
E[Ygsk] = β0gk + β1gkXs + β2gkZk + β3gkXsZk, (2.18)
where Xs is an indicator variable for the tissue type of sth sample, and Zk is an indicator
variable for the study. The model could be fit using ordinary least squares. All of the three
methods provided by Ghosh et al. treat genes independently, so that genes are fitted using
the above models independently and the false discovery rate is controlled in the end.
Choi et al. (2003) implemented the same random effects models described in section
2.1.2 for each gene. They suggested a quantile-quantile plot of the observed versus expected
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Cochran’s Q values over all genes to explore the homogeneity in multiple studies. If the plot
approximates a straight line, especially near the center, the presumption of a Chi-square
distribution is appropriate suggesting that the datasets might be sampled from a common
population and that only the sampling error is present, so a simple fixed effect model is
enough. If this is not the case we have to fit a random effects model. They further discussed
the Bayesian interpretation for the REM model. Following the same notation from section
2.1.2, the model is written as
p(µ, θ1, . . . , θK , τ
2|T1, . . . , TK)




p(θk|Tk, σ2k)p(θk|µ, τ 2)pi(µ)pi(τ 2)
where pi(µ) and pi(τ 2) are non-informative priors given as µ ∼ N(0, 106) and 1/τ 2 ∼
gamma(0.001, 0.001).
Similar Bayesian hierarchical models have been suggested by Tseng et al. (2001) and
Conlon and Liu (2005) for incorporating different levels of replicates information in cDNA
microarray experiments. Unlike the approach of Choi et al., which estimates the gene effects
first and then put the effect size into the model, Tseng et al. and Colon and Liu present
Bayesian hierarchical models based on gene expression levels across studies. Let ygesk denote
the normalized log-expression ratios of gene g, experiment e, and slide s in study k. For each
study ygesk is sampled from a normal distribution of the slide effect within experiment and
study. The hierarchical model is as follows:
ygesk|µgek ∼ N(µgek, τ 2gk)
µgek|θgk ∼ N(θgk, σ2gk)
θgk|Ig = 0 ∼ N(0, η2gk0) (2.20)
θgk|Ig = 1 ∼ N(0, ck × η2gk0)
Ig ∼ Bernoulli(p)
p ∼ Uniform(0, 1).
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τ 2gk explains the variation in the slide effect within study k. Further, µgek is sampled from
a normal distribution with mean θgk, and σ
2
gk explains the variation within study k. Genes
are divided into two groups, non-expressed (Ig = 0) and expressed (Ig = 0), so that p =
Pr(Ig = 1). Genes are determined as differentially expressed if the posterior probability
Dg = Pr(Ig = 1|data) is greater than a threshold.
Owen (2007) re-introduced Pearson’s method and applies it to the AGEMAP project. In
the AGEMAP project 40 mice were studied with different ages. The samples were from 16
different tissues. To investigate the association between gene expression and age, an ordinary
regression can be fitted. Let βgk be the age slope for gth gene in study k. The null hypothesis






g ), where V
EW ;L
g =
−∑Kk=1 log(p˜gk), V EW ;Rg = −∑Kk=1 log(1− p˜gk) and p˜gk is the is the one-sided p-value pgk =
Pr(|βˆsk| ≤ |bˆsk||H0,gk) of gene g in study k. Clearly, this test statistic is a modification of
Fisher’s method by combining one-sided p-values. A similar modification could be done to









−1(p˜gk), V Z;Rg =
−∑Kk=1Φ−1(1− p˜gk). He claims that V EW∗g and V Z∗g are sensitive to either consistently left
or right sided departure. And he further investigates the relative effectiveness of Vg∗, V ·;Rg
and V ·:Lg in detecting alternate hypotheses that vary in a consistent direction from the null.
As expected, V ·;Rg is more sensitive to positive slopes and for negative slopes, V
·;L
g is the best
choice. The method, however, is still easily dominated by one or two extremely significant
p-values and does not tell which studies are significant for distinguishing concordant genes
and discordant genes (see Chapter 3).
Breitling et al. (2004) proposed the rank product method for detecting regulated genes
in replicated microarray experiments. Hong et al. (2006) modified and extended the rank
product method to accommodate the analysis of multiple microarray studies. For a study
k with two groups (rsk = {0, 1}), denote n0k and n1k as the number of replicates for group
0 and 1 respectively. They first calculate the pair-wise fold changes between two groups for
each gene within the study, that is, FCgkt = (ygki|rsk = 1)/(ygkj|rsk = 0), i ∈ (rsk = 0) and
j ∈ (rsk = 1). There are n0k × n1k pairs. For K studies, there are a total of
∑K
k=1 n0k × n1k
pairs. So t = 1, . . . ,
∑K
k=1 n0k × n1k. The rank product statistic for each gene is defined




1/K , where rgt is the rank of FC of the gth gene under the
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tth comparison. The null distribution of V RP is then determined from permutation. For
genes regulated in the opposite direction, they swap the the groups and perform the same
algorithm once more. Since this method combines ranks instead of real gene expression,
fewer assumptions are needed. They also claim that it overcomes the heterogeneity among
multiple datasets.
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3.0 OPTIMALLY WEIGHTED STATISTIC FOR COMBINING MULTIPLE
MICROARRAY STUDIES
3.1 BACKGROUND
Integrating results from different studies is commonplace in a wide variety of biological
applications. Significance levels and effect sizes are two common metrics utilized in meta
analysis. The random effects model is often used to incorporate random effects caused by,
for example, variations of sampling schemes in different studies. In many applications, data
structures and statistical hypotheses may differ, making a direct combination of effect sizes
impossible. It becomes more feasible to combine the transformed probability integrals of
test statistics (usually p-values) - a procedure that depends only on the significance values
of individual tests and not on the underlying data structure. The well-known method in this
category was proposed by Fisher (1932). The test statistic involves the log-transformation




where K studies are combined and pk is the p-value of study k, 1 ≤ k ≤ K. Assuming both
independence among studies and the p-values calculated from correct null distributions in
each study, 2V EW follows a Chi-square distribution with 2K degrees of freedom. A large
number of different transformations have been considered in the literature - for example,
inverse normal, logit and inverse Chi-square transformation with varying degrees of free-
dom (Stouffer et al., 1949; Lancaster, 1961; George, 1977). While Fisher’s method is not
a uniformly most powerful test, it has strong support in the literature for its good power
under a wide range of alternative conditions and for being the most asymptotically Bahadur
optimal (ABO) among several commonly used combined tests (Little and Folks, 1971, 1973).
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Different weights and variations of the test statistic have also been considered. Good (1955)
suggested using unequal weights for each individual study, and Olkin and Saner (2001) pro-
posed a trimmed version of the Fisher procedure to remove the effect of possibly aberrant
extremes. Another well known method in this category is Tippetts (1931) minimum p-value
statistic: V minP = min1≤k≤Kpk. Wilkinson (1951) generalized Tippetts procedure to a more
robust rth smallest p-value. It is worth noting that the minimum p-value (minP) and max-
imum p-value statistics (maxP) are special cases of the union-intersection test (UIT) (Roy,
1953) and the intersection-union test (IUT) (Berger, 1982) respectively. For a comprehensive
review and comparison of different approaches, see Hedges (1992) and Cousins (2007).
Microarray technology allows researchers to examine the expression of thousands of genes
in parallel. With microarray experiments becoming more mature and prevalent, the inte-
gration of homogeneous experimental data sets from multiple laboratories and experimental
techniques has become imperative. In contrast to traditional epidemiological or evidence
based medical studies, microarrays monitor gene expression for thousands of genes simulta-
neously - a process that brings challenges to integrative analysis. Currently “meta-analysis”
in the biological literature consists of a widespread use of naive “intersection” and/or “union”
operations on differentially expressed gene lists obtained from individual studies by certain
criteria (e.g. False Discovery Rate ≤ 0.05) (Segal et al., 2004, Borovecki et al., 2005, Cardoso
et al., 2007, Pirooznia et al., 2007, and many more). One can quickly note that intersections
are often too conservative and unions are anti-conservative, especially as K increases. Rhode
et al. (2002) was the first to apply Fisher’s method to microarray data for a real sense
of meta-analysis. They later introduced a weighted average of test statistics of individual
tests, with the weights determined in an ad hoc manner according to sample sizes in the
studies (Ghosh et al. 2003). Choi et al. (2003) pointed out that the approach in Rhode
et al. “ignored the interstudy variation” and they proposed a random effects model (REM)
under Gaussian assumptions and further discussed the details of a Bayesian formulation for
the REM model. Similar Bayesian hierarchical models have been suggested by Tseng et al.
(2001) and Conlon and Liu (2005) for incorporating different levels of replicates information
in cDNA microarray experiments.
In this chapter, we propose an optimally weighted (OW) statistic for the meta-analysis
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of multiple genomic studies. In contrast to the equally weighted (EW) statistic in Fishers
method, the OW statistic finds the optimal weight that provides the best statistical signif-
icance. In Section 3.2, two complementary hypothesis settings (HS1 and HS2) are outlined
and all meta-analysis methods targeted for their respective hypothesis settings are clarified.
The remaining part of the chapter (Section 3.3-3.6) is devoted to the HS1 framework to
discuss the comparison and properties of the OW statistic. In Section 3.3, we introduce
the idea of the OW statistic and a detailed algorithm implementing the OW statistic and
permutation test is outlined for integrating multiple genomic studies. In Section 3.4, we
demonstrate the admissibility of OW, EW and minP in the traditional two sample compari-
son under Gaussian assumption and the power of OW is compared to EW and minP. Section
3.5 presents a simulation study and applications to a set of multi-tissue energy metabolism
mouse data and a set of three prostate cancer expression profiles. Finally we summarize and
discuss the advantages and limitations of the OW statistic in Section 3.6.
3.2 TWO COMPLEMENTARY HYPOTHESIS SETTINGS
In the existing meta-analysis methods applied to genomic data discussed above, no compre-
hensive evaluation has been performed. A major reason is the lack of rigorous formulation of
hypothesis settings behind these methods. We consider meta-analysis of K gene expression
profile studies: D1, D2, . . . , DK . In each study Dk, xkgs is the gene expression intensity of
gene g and sample s, where samples s = 1, . . . , nk belong to a control group (e.g. normal
patients) and s = nk + 1, . . . , nk +mk belong to the target group (e.g. tumor patients). We
define the first hypothesis setting as:
HS1 : H0g : θg1 = θg2 = . . . = θgK = 0 versus HAg : at least one θgk 6= 0, 1 ≤ k ≤ K,
where θgk is the parameter that characterizes the effect of study k in gene g,1 ≤ g ≤ G. HS1
corresponds to the biological question Q1: “which genes are differentially expressed in one or
more data sets among the K studies?”. This question is often addressed when heterogenous
characteristics are expected across studies (e.g., differential sample population, experimental
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quality or tissues collected across studies). See the example in Section 5.2 where three
tissues are examined and tissue specific physiology is expected. Another commonly asked
biological question in the meta-analysis of microarray studies would be Q2: “which genes are
differentially expressed in all data sets among the K studies?”. The corresponding hypothesis
setting is:
HS2 : H0g : at least one θgk = 0 versus HAg : θgk 6= 0, 1 ≤ k ≤ K.
This question is often asked when studies have homogeneous characteristics. Significance
in all studies is demanded to generate highly confident biomarkers and combining multiple
studies increases the statistical power.
Among the methods discussed in Section 3.1, EW, minP and the proposed OW statistic
are designed to answer the HS1 problem, while REM and maxP are methods for HS2. In this
chapter, we will only focus on the HS1 problem and compare the three major methods EW,
minP and OW to demonstrate the properties and advantages of the proposed OW method.
3.3 OPTIMAL-WEIGHTED STATISTIC
When integrating multiple genomic studies, expression of some genes may be altered in a
study specific manner (consider HS1). To uncover the pattern of altered gene expression





where pgk is the p-value of gene g in study k, wk is the weight assigned to the kth study
and w = (w1, . . . , wk). Under the null hypothesis that θgk = 0∀k in HS1, the p-value of the
observed weighted statistic, p(ug(w)), can be obtained for a given gene g and weight w (see
below for detailed permutation algorithm to calculate the p-value). The optimally-weighted
statistic is defined as the minimal p-value among all possible weights:




where ug(w) is the observed statistic for Ug(w) and W is a pre-specified search space. Our
choice of search space in this chapter is W = {w|wi ∈ {0, 1}}, which results in an affordable
computation of O(2K − 1) based on the norm of K ≤ 10 in a microarray meta-analysis.
The resulting optimal weight reflects a natural biological interpretation of whether or not
a study contributes to the statistical significance of a gene. We note that the OW statistic is
not adequate for the traditional meta-analysis in epidemiological or evidence-based medicine
research. The selection procedure in OW will introduce selection bias towards studies with
concordant significant effects. The meta-analysis of genomic studies, however, is quite a
different situation. The major goal is usually to screen and identify the most probable gene
markers given data to facilitate future investigation. As we will show in section 3.5, the
vector of optimal-weight, w∗g = argminw∈W p(ug(w)), actually serves as a convenient basis
for gene categorization in follow-up biological interpretation and exploration.
Below we illustrate the detailed procedure for OW when applied for combining genomic
studies. A permutation test is performed to assess the statistical significance and false
discovery rate (FDR) is controlled at 5%. For the applications in Section 3.5, the minP and
EW methods are performed using a similar permutation test.
I. Study-wise p-value calculation before meta-analysis:
1. Compute the moderated t-statistics, {tgk for gene g and study k. (Efron et al., 2001;
Tusher et al., 2001)
2. Permute group labels in each study for B times, and similarly calculate the permuted
statistics {t(b)gk ; 1 ≤ g ≤ G, 1 ≤ k ≤ K, 1 ≤ b ≤ B}.







, where R(tgk) is the rejection













II. Calculate OW statistic:
1. Given a weight w = (w1, . . . , wk), calculate the weighted statistic ug(w) = −
∑K
k=1wklog(pgk)
for gene g. Define u
(b)
g (w) = −∑Kk=1wklog(p(b)gk ).





















3. Based on II.A. (1) and II.A.(2), calculate the optimal weight as w∗g = argminw∈W p(ug(w))
and similarly w
(b)∗
g = argminw∈W p(u
(b)
g (w)). Define the OW statistic Vg as the p-value
of the optimally weighted statistic: Vg = p(Ug(w∗)). Similarly V (b)g = p(U (b)g (w∗)).
III. Assess p-values and q-values:








2. Estimate pi0 , the proportion of null genes, as pi0 =
∑G
g=1 I{p(Vg)∈A}
G·`(A) (Storey 2002). Normally
we choose A = [0.5, 1] and `(A) = 0.5.











. The detected gene
list is GOW = {g : q(Vg) ≤ 0.05}.
IV. Distinguish concordant and discordant genes (optional): Split the detected gene
list GOW into concordant and discordant gene lists. Detected genes with concordant reg-
ulation direction across significant studies are denoted as GOWconcord = {g : q(Vg) ≤ 0.05 |
|∑Kk=1 sgn(tgk) · w∗gk| =∑Kk=1w∗gk},where sgn(·) is the sign function that takes the value of
1 when positive and -1 when negative. The discordant gene list is GOWdiscord = G
OW \GOWconcord.
Remarks:
1. For the application of the EW and minP method, step II.(1)-II.(3) can be skipped. Alter-
natively the test statistic are modified as Vg = −
∑K
k=1 log(pgk) and V
(b)
g = −∑Kk=1 log(p(b)gk )





2. The sequence I., II. and III. provides an algorithm for a general framework. The statistics
tgk and the rejection region R(tgk) can be replaced depending on the experimental design
and hypothesis. For example, the F-statistic can be used when multiple groups of samples
are available in each study.
3. When conducting two group comparisons and applying moderated t-statistics, genes de-
tected under the general framework (sequence I., II. and III.) may contain discordant
genes (i.e. a gene up-regulated in one study and down-regulated in another). The ad-
dition of step IV. provides further filtering to solve the problem. In some applications,
it may be of interest to scrutinize the discordant gene list to verify whether the discor-
dance reflects real biological discrepancy across studies (e.g. different tissues or patient
populations) or is caused by artificial errors (e.g. mistakes in gene annotation). For
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EW and minP, there is no direct criterion for a clear split of concordant and discordant
genes. Pearson (1938) and Owen (2007) proposed a modification for EW that is sensitive











k=1 log(1− p˜gk) and p˜gk is the is the one sided
p-value of gene g in study k. The method, however, is still easily dominated by one
or two extremely significant p-values and does not tell which studies are significant in
distinguishing concordant versus discordant (see examples in Section 3.5.2).
4. Several forms of penalized or moderated t-statistics have been proposed and shown to
outperform traditional t-statistics (Efron et al., 2001; Tusher et al., 2001; Smyth et al.,
2004; ). In our algorithm, we choose the penalized t-statistics used in Efron et al. (2001)
and Tusher et al. (2001). The fudge parameter s0 is chosen to be the median variability
estimator in the genome.
5. In III.(2), many reports have indicated the intrinsic difficulty in estimating pi0 and a poor
estimator pi0 can greatly deteriorate the FDR estimation. A conservative suggestion is
to set pi0 = 1 all the time and is applied in this chapter.
3.4 ADMISSIBILITY AND POWER
In this section, we drop the subscript g for genes and compare three test statistics (EW, OW
and minP) for HS1 at the univariate level assuming independence between studies. To date,
no best method for combining multiples studies has been identified, therefore choosing a
combined statistic must reflect specific biological purposes. Birnbaum (1954) provided gen-
eral conditions for evaluating combined methods, including monotonicity and admissibility.
He (Birnbaum, 1955) further compared several combined test procedures by considering a
one-sample test on the mean of a Gaussian distribution with known variance. Here we will






.k = 1, 2, . . . , K. (3.3)
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and the two-sided p-value Pk = Pr(|Z| ≥ |zk||θ = 0) for each study to examine the accep-
tance region of the different combined test procedures. We will discuss the admissibility and
compare the power of the three test statistics under this simplified framework.
3.4.1 Admissibility
A test is considered admissible if it cannot be uniformly improved by any other test. It is
well-known that no uniformly most powerful test exists even in the simplified scenario (3.3).
Birnbaum stated a necessary and sufficient condition for a test to be admissible under this
situation.
Theorem 3.4.1. (Birnbaum 1954, 1955) Under HS1 and assumption (3.3), a necessary and
sufficient condition for a combined test procedure to be admissible is that the corresponding
acceptance region is convex.
It has been noted that the acceptance regions of EW and minP are both convex and
thus both methods are admissible. Figure 1 shows the acceptance regions of EW, minP
and OW in the plane of a pair of Z statistic at level 0.05. When illustrating the rejection
regions of several common combined tests (including EW and minP), Birnbaum showed a
preference for the EW method in most cases because it appeared to be fairly sensitive in all
directions. From Figure 1, we observe that OW actually shares merits from both EW and
minP. It is more sensitive than the minP method when parameters from both studies depart
from 0 and more sensitive than EW when only one of the parameters departs from 0. The
following corollary shows that the acceptance region of OW is also convex and thus OW is
also admissible.
Corollary 3.4.2. The acceptance region of OW is convex and thus OW is admissible under
HS1 and assumption (3).
Proof: Denote by pk = 1 − Φ(|zk|) the two-sided p-value,where Φ(t) =
∫ t
−∞ φ(t)dt, φ(t)
is the density of the standard normal distribution. First we prove that f(zk) = −log(pk) =
−log(1 − Φ(|zk|)) is convex. f ′′(z) = φ(|z|)[1−Φ(|z|)]2{φ(|z|) − |z|[1 − Φ(|z|)]}. It is well known
that the elementary upper bound for 1 − Φ(x) is φ(x)/x, for x > 0. Thus, f ′′(z) > 0.
So f(z) is convex in z. Hence f(z1, z2, . . . , zK) = −
∑n
k=1 log(pk) for ∀n ≥ 1 is convex,
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Figure 1: Acceptance regions of Equal-Weighted, Optimal-Weighted, minimum p-value and
maximum p-value methods of combining p-values from two independent studies.
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because the sum of convex functions is convex. For the OW statistic, the acceptance region
is {z1, z2, . . . , zK : min0≤k≤K p(u(w)) > c}, where p(u(w)) is the right-sided p-value of u(w).






{z1, z2, . . . , zK : p(−
K∑
k=1




{z1, z2, . . . , zK : −
K∑
k=1
log[pIkk ] < γj}, j = 1, 2, . . . , 2K − 1
(3.4)
Thus the acceptance region of OW is convex since the intersection of convex sets is also
convex.
Note that when K = 2, {z1, z2 : minw∈W p(u(w)) > c} = {z1, z2 : min(p1, p2) >
c}⋂{z1, z2 : −log(p1p2) ≤ γ}, the acceptance region of the OW method is an intersection of
minP and EW.
3.4.2 Power comparison of EW,OW and minP under HS1
Denote by θ = (θ1, . . . , θK) the vector of parameters characterizing the studies and by
βOW (θ;α) the power of a test controlled at level α, for the OW statistic, we have







p(Pk|θ)dP1 . . . dPK , (3.5)
where Ω : {⋂2K−1i=1 p(u(wi)) > COWα } = {⋂2K−1i=1 U(wi) < F−1Gamma(∑Kk=1 wki,1)(1 − COWα )} and
F−1Gamma(α,β) is the inverse CDF of Gamma distribution with parameters α and β, wi =
(w1i, . . . , wKi), wki ∈ {0, 1}, k = 1, . . . , K. COWα is the solution of v to the equation P (V OW ≤
v|H0) = α. If the null hypothesis of HS1 was true, it is generally accepted that the individual
Pk value is a uniform random variable on [0,1]. The density of the P value under the
alternative law is given by
p(P |θ) = p(x|θ)
p(x|0) |x=g(P ) (0 ≤ P ≤ 1), (3.6)
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. We consider K = 2 and 8 , nk1 = nk2 = 5, σk = 1, so that the
effect size is represented by θk. Power is evaluated with varying effect sizes.
Figure 2 illustrates the power curves under different alternative hypotheses when com-
bining eight studies. As expected, when only one of the eight studies are significant, minP is
much more powerful than EW (Figure 2.(a)) and when all of the eight studies are significant,
EW is much more powerful than minP (Figure 2.(d)). On the other hand, OW performs
stably near the best in the two extreme situations and is the top performer when two or
three out of eight studies are significant (Figure 2.(b) and (c)).
3.5 APPLICATIONS
3.5.1 Simulation study
We conducted a simulation study for combining four datasets to assess the performance of
our proposed optimally-weighted statistic (OW), Fisher’s equally-weighted statistic (EW)
and Tippett’s minimum p-value method (minP); and naive union (union of DE gene lists
from each individual study controlled at FDR=5%) was also included for comparison. For
each dataset, we simulated five normal samples from a standard normal distribution and five
case samples from a N(θ, 1). A total of g1 genes (category I) were differentially expressed
across all four data sets. In contrast, g2 = 400− g1 genes were differentially expressed only
in the fourth data set (category II), and 1600 genes were considered null. The FDR was
controlled at 5% for each method, and each simulation was repeated 1000 times.
Summaries of the resulting FDR and average number of genes identified in each category
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Figure 2: Power analysis of EW, OW, minP under HS1. We compare power curves of the
three methods combining eight studies under different alternative hypotheses: (a) One of
the eight hypotheses is false; (b) Two of the eight hypotheses are false; (c) Three of the eight
hypotheses are false; (d) All of the eight hypotheses are false.
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Table 4: Average number of genes detected in each category (I. 0 common DE genes; II.
400 4th-dataset-specific DE genes; Null. 1600 random noise genes), and average FDR,
according to different θ.
Methods θ = 2.0 θ = 2.5 θ = 3.0
I II Null FDR I II Null FDR I II Null FDR
OW 0.0 7.5 0.5 7.0%a 0.0 35.5 1.6 4.7%a 0.0 142.4 7.6 5.0%a
EW 0.0 3.4 0.3 7.1%a 0.0 13.2 0.7 5.4%a 0.0 65.8 3.7 5.4%a
minP 0.0 9.3 0.6 6.5%a 0.0 66.6 3.8 5.8%a 0.0 173.5 9.1 5.5%a
Union 0.0 117.2 6.2 4.8%a 0.0 265.0 13.2 4.6%a 0.0 352.2 17.7 4.7%a
aestimated FDR (mean of Null/(I+II+Null)) for HS1.
Table 5: Average number of genes detected in each category (I. 200 common DE genes;
II. 200 4th-dataset-specific DE genes; Null. 1600 random noise genes), and average FDR,
according to different θ.
Methods θ = 1.5 θ = 2.0 θ = 2.5
I II Null FDR I II Null FDR I II Null FDR
OW 109.7 10.7 6.2 4.8%a 189.2 37.4 11.2 4.8%a 199.7 72.2 13.2 4.6%a
EW 154.0 11.6 8.6 4.9%a 197.4 28.2 11.5 4.8%a 200.0 49.6 12.5 4.7%a
minP 3.6 0.9 0.4 6.1%a 76.1 22.6 4.8 4.5%a 168.0 72.5 11.6 4.5%a
Union 8.9 4.7 1.1 7.3%a 91.9 58.0 9.6 6.3%a 185.8 132.9 24.1 7.0%a
aestimated FDR (mean of Null/(I+II+Null)) for HS1.
Table 6: Average number of genes detected in each category (I. 400 common DE genes;
II. 0 4th-dataset-specific DE genes; Null. 1600 random noise genes), and average FDR,
according to different θ.
Methods θ = 1.5 θ = 2.0 θ = 2.5
I II Null FDR I II Null FDR I II Null FDR
OW 268.5 0.0 13.9 4.9%a 386.6 0.0 19.4 4.8%a 399.6 0.0 18.8 4.5%a
EW 339.6 0.0 17.9 5.0%a 397.3 0.0 20.6 4.9%a 400.0 0.0 19.8 4.7%a
minP 22.1 0.0 1.3 4.8%a 230.6 0.0 11.4 4.6%a 359.9 0.0 16.7 4.4%a
Union 36.9 0.0 2.6 6.1%a 298.9 0.0 24.1 7.4%a 394.8 0.0 51.9 11.6%a
aestimated FDR (mean of Null/(I+II+Null)) for HS1.
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category II genes; Table 5, 200 category I and 200 category II genes; Table 6, 400 category I
and 0 category II genes. The result is consistent with the power calculation in Section 4.2.
In Table 4, minP is much more powerful than EW. When θ = 3, minP detects an average
of 173.5 genes and EW detects only 65.8 genes. OW, on the other hand, finds 142.4 genes,
which is quite close to minP. Similarly in Table 6, EW (397.3 genes detected when θ = 2) is
more powerful than minP (230.6 detected genes) and OW (386.6 detected genes) is close to
EW in performance. Overall OW performed stably well in the two extreme situations. We
note that the naive union method generally loses control of FDR as expected.
3.5.2 Energy metabolism in mouse model
The deficiencies of very long-chain acyl-coenzyme A dehydrogenase (VLCAD) are associated
with an energy metabolism disorder in children. Two genotypes of mouse model (wild
type (VLCAD +/+) and VLCAD-deficient (VLCAD -/-)) are studied with four mice in
each genotype group. For each of the 8 mice, three types of tissues (brown fat, liver and
heart) were applied separately in microarray experiments to study the expression changes
across genotypes. In this study, one of the hypotheses is that tissue-specific physiology
triggers tissue-dependent responses, with precise pools of differentially expressed genes being
confounded to the tissue in question. This hypothesis is aimed at understanding signature
genes that are significant for tissue subsets, an analysis that corresponds to HS1.
In Figure 3, OW, EW, Pearsons method (described in Remark 3 of Section 3.3) and minP
are implemented. The modified algorithm of OW for filtering out discordant genes (step IV in
Section 3.3) is also implemented. It discards all genes that contain discordance among studies
contributing to the optimal weight. We note that the modified algorithm is not applicable
to EW, Pearson’s method and minP since these methods do not provide indication of which
studies to consider for concordance/discordance evaluation. Overall the general OW detects
203 genes in Figure 3(a) and among them, 28 genes have conflict up or down regulations (i.e.
Figure 3(b) detects 175 genes). The optimal weights provide natural grouping of identified
genes. For example, 55 genes with (1,1,1) optimal weight are differentially expressed in all
three tissues in Figure 3(b) and 27 genes with (0,1,1) weight are statistically significant only
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in liver and heart tissues, but not in brown fat. Results of the EW method are presented in
Figure 3(c). It detects more genes than OW (329 genes). The identified gene list is, however,
difficult to interpret and investigate even after gene reordering by hierarchical clustering. We
note that minP seems to be much less powerful in this application. We note that EW, minP
and OW are based on summarization of p-values across studies. The methods alone do not
distinguish discordant genes that have differential expression across studies. The method
presented by Owen (2007), previously proposed by Pearson (1934), was developed to modify
EW for this purpose. Table 7 shows five example genes. The first two genes (1419182 at and
1423407 a at) contain clear discordant regulation across studies. All of the four methods
except for minP identify them as differentially expressed genes. Pearson’s method, designed
for detecting only concordant genes, failed to achieve the goal to exclude such discordant
genes. In the OW method, the optimal weight enables a post-hoc approach (Step IV in
Section 3.3) to filter out these discordant genes. For EW, minP and Pearson’s method, such
a post-hoc procedure is not feasible without indication of which studies are differentially
expressed. For example, in the last two examples of Table 7 (1449015 at and 1416415 a at),
the OW method with concordance filtering will still call it a concordant DE gene although
the regulation of the non-significant study (brown fat) contradicts the other two significant
studies.
3.5.3 The Prostate cancer studies
We applied the algorithm to three publicly available prostate cancer gene expression datasets
(Dhanasekaran et al., 2001; Luo et al., 2001; Welsh et al., 2001) independently collected in
separate medical centers: two representing cDNA technology and one oligo-based technology.
Probes of the three datasets were matched by UniGene ID. Gene expression comparisons were
made between clinically localized prostate cancer and benign prostate tissue. The results
presented in Figure 4 reflect the methods similar characteristics as seen from the mouse
data. With an exception, minP does not perform as poorly as in Section 3.5.2 and a larger
number of genes are detected. The OW method shows much clearer patterns than the other
methods. Of the 722 genes in Figure 4(a), 618 genes show consistent regulation across studies
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Figure 3: Heatmap of gene expressions for differentially expressed genes identified according
to different methods in analyzing mouse data. Each row represents a single gene, each
column represents a sample. The data were normalized within each tissue. In OW, genes
are ordered by hierarchical clustering in each category formed by gene specific best weight.
Genes identified from the other methods are ordered by hierarchical clustering.
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Table 7: Five example genes from the mouse energy metabolism data
Gene moderated-t statistic (p-value) p-value(q-value) for meta analysis methods
Brown fat Liver Heart OW EW minP Pearson
1419182 at -3.3(0.0004) 1.6(0.0190) -1.9(0.0109) 0.0005 0.00001 0.0011 0.0004
w∗ 1 1 1 (0.030) (0.001) (0.088) (0.012)
1423407 a at 2.2(0.0027) 1.7(0.0121) -3.7(0.0014) 0.0004 0.0001 0.0041 0.0018
w∗ 1 1 1 (0.031) (0.001) (0.112) (0.034)
1418429 at 3.6(0.0003) 1.1(0.0672) -3.2(0.0020) 0.0001 0.0001 0.0008 0.0010
w∗ 1 0 1 (0.028) (0.001) (0.088) (0.023)
1449015 at 0.4(0.4558) -3.3(0.0009) -1.8(0.0110) 0.0008 0.0007 0.0017 0.0005
w∗ 0 1 1 (0.020) (0.016) (0.056) (0.012)
1416415 a at -0.80(0.1496) 2.24(0.0026) 2.58(0.0023) 0.0012 0.0003 0.007 0.0005
w∗ 0 1 1 (0.035) (0.011) (0.089) (0.012)
and are shown in Figure 4(b). About 14% discordant genes are observed. Causes of such
discordant genes may include mistaken gene annotation in old array platforms (Dai et al.,
2005), differential probe efficiencies, heterogeneous sample populations across studies and
non-specific cross hybridizations. The findings suggest that results obtained from individual
microarray studies require careful interpretation, and that synthesized analyses provide more
powerful tests and appropriate validation.
3.6 DISCUSSION
In this chapter, we propose an optimally weighted statistic for combining multiple studies
and applied it for combining microarray studies. The evaluation of meta-analysis methods
heavily depends on the biological question being investigated and the corresponding statis-
tical hypothesis settings. We formulated two hypothesis settings, HS1 and HS2, to identify
differentially expressed genes considered significant in either partial data sets or in all data
sets. The classical EW, minP and proposed OW methods were targeted on HS1 and are
discussed in this chapter. We showed that OW, as well as EW and minP, were all admis-
sible under a simplified scenario considered. In the power analysis, EW was more powerful
when all data sets were significant and minP was more powerful when only one or few data
sets were significant. The OW method, which can be viewed as a compromise between EW
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Figure 4: Heatmap of gene expressions for differentially expressed genes identified according
to different methods in analyzing prostate cancer data. Each row represents a single gene,
each column represents a prostate sample. The data were normalized within each study. In
OW, the genes are ordered by hierarchical clustering in each category formed by gene specific
best weight. Genes identified from the other methods are ordered by hierarchical clustering.
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hypothesis settings (Figure 2). Simulation results also confirmed this robust property of
OW (Table 4-6). In the applications, OW expressed an additional advantage of categoriz-
ing differentially expressed genes by their optimal weights, thus providing a practical basis
for further biological exploration. The modified algorithm in Section 3.3 procedure II.B.
avoided detection of genes with discordant regulation direction and was appealing for the
specific biological purpose.
There are a few limitations and possible future extensions for this work. Firstly we
assumed all studies contain identical matched gene list and no missing values. In practice,
studies to be combined usually come from different microarray platforms. Requiring an iden-
tical matched gene list and no missing values will exclude many important genes appearing
in one study but not in another. An extension allowing missing values will be necessary. Sec-
ondly we focused on the two-group comparison in this chapter and provided a modification
for detecting only genes with concordant expression changes. For comparison of more than
two groups, the F-statistic and its variations can be applied and the resulting p-values can
be combined similarly. Small p-values across studies, however, do not guarantee concordant
expression patterns. We are currently developing a pair-wise correlation approach to replace
p-values for this problem.
While this chapter only considered combining multiple microarray studies, the methods
can easily be extended for combination of multiple genomic, epigenomic and/or proteomic
studies for instance, data sets from SNP arrays, genome arrays, methylation arrays, pro-
teomic experiments and ChIP-on-chip experiments.
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4.0 MINIMUM MULTI-CLASS CORRELATION STATISTIC WHEN
COMBINING MULTIPLE MULTI-CLASS MICROARRAY STUDIES
4.1 BACKGROUND
Microarray technology provides an opportunity for global monitoring of gene expression ac-
tivities. As the technology matures and becomes prevalent in biomedical research, many
data sets have been accumulated in the public internet domain; for example, the NCBI Gene
Expression Omnibus (Edgar et al., 2002), the EBI ArrayExpress (Parkinson et al., 2005) and
the Stanford Microarray Database (Sherlock et al., 2001). The development of effective in-
formation integration of multiple microarray studies has gained increasing attention. Among
the various types of microarray statistical analysis, detection of differentially expressed (DE)
genes is one of the most important goals. Samples under two different conditions (e.g. normal
versus diseased patients) are examined. Many statistical methods have been proposed for
detecting biomarkers differentially expressed across the two classes (Breitling et al., 2005;
Efron et al., 2001; Newton et al., 2004; Tusher et al., 2001). When multiple microarray
studies are available, meta-analysis is expected to increase statistical power for DE gene
detection. Rhode et al. (2002) was among the first to apply the traditional Fisher’s method
(Fisher, 1948) for combining multiple microarray studies. Many other approaches have been
proposed later, including a lasso-based method (Ghosh et al., 2003), random effects models
(Choi et al., 2003; Stevens and Doerge, 2005), Bayesian methods (Tseng et al., 2001; Jung
et al., 2006; Conlon et al., 2007), rank-based approaches (Breitling et al., 2005; Hong et
al., 2006) and others. Recently Li and Tseng (2008) elucidated two statistical hypothesis
settings behind two separate biological goals in combining multiple array studies: (1) HS1:
detecting biomarkers statistically significant in one or more studies, and (2) HS2: detecting
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highly confident biomarkers differentially expressed in all studies. An optimally-weighted
statistic was modified from the Fisher’s score and was proposed for the former hypothesis
setting. The optimal weights provided natural categorization of the detected biomarkers
for further biological investigation. So far, most of the methods in the literature, including
those described above, focus on the two-class “disease-versus-normal” setting. Combining
data sets with more than two classes is rarely discussed.
In general, two metrics are commonly combined in the meta-analysis. The first is to
combine the effect sizes of each study to generate a conclusion of overall effect size and
its confidence interval, which is commonly seen in the research of evidence-based medicine.
Random effects model, for example, is a popular method in this category. The second metric
combines significance levels or their transformation scores. The famous Fisher’s method
belongs to the category that sums up the log-transformed p-values. Many other statistics
including trimmed version of Fisher’s method (Olkin and Saner, 2001), minimum p-value
(Tippett, 1931) and Wilkinsons rth smallest p-value (1951) have also been considered. It
is worth noting that the former metric is only valid in the two-class comparison. When
more than two classes are considered, no single effect size can be computed and, instead, the
patterns (between-group fluctuation of the group means) become the concern. The latter
category is, however, extensible to data sets with more than two classes. The F-statistic (or
equivalently ANOVA model) and its variants can be applied and p-values can be assessed
and combined across studies.
In this chapter, we explore the method of ANOVA-maxP, which detects biomarkers with
a significant pattern (large between-group variation versus small within-group variations) in
all studies. We also note that small p-values (equivalently large F-statistics) in all studies
do not guarantee a consistent pattern across studies. Figure 5 shows two example genes
detected by ANOVA-maxP where the patterns across studies are not consistent.
To overcome this issue, we develop a pairwise multi-class correlation (MCC) measure.
The correlation measure is defined through an equal-weight bivariate mixture model from
the multi-class observations. A min-MCC algorithm is extended for combining multiple
studies and the method guarantees the detection of only concordant pattern biomarkers. The

























































Figure 5: Two genes from the mouse metabolism data and detected by ANOVA-maxP. The
patterns across tissues are lowly or negatively correlated. Box-plots of each genotype in each
tissue are plotted and the mean expression levels are connected. Upper: expression pattern
of Acsl5 (involved in fatty acid degradation pathway). Lower: expression pattern of gene
Scd1 (involved in fatty acid synthesis pathway).
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Table 8: Sample information of the mouse metabolism
data set.
Tissue type Brown fat Liver Heart Skeletal totalGenotypea 1 2 3 1 2 3 1 2 3 1 2 3
Number of arrays 4 4 4 4 4 4 3 4 4 3 3 3 44
a1: Wild type; 2: VLCAD -/-; 3: LCAD -/-.
to a multi-platform mouse trauma data set and a multi-tissue mouse energy metabolism data
set. The result shows that ANOVA-maxP detects both concordant and discordant genes and
min-MCC detects only concordant genes. The two methods are complementary and serve
different biological purposes.
4.2 METHODS
4.2.1 Data description and notation
Two real data sets are used to evaluate proposed methods. The first data set involves
samples from three genotype mice: wild-type (WT), LCAD knock-out (LCAD -/-) and
VLCAD knock-out (VLCAD -/-). Deficiency of very long chain acyl-CoA dehydrogenase
(VLCAD) is known to be related to a common energy metabolism disorder in children.
On the other hand, LCAD (long-chain acyl-CoA dehydrogenase) deficient mice are known
to have impaired fatty acid oxidation and develop a disease similar to other disorders of
mitochondrial fatty acid oxidation. For each of the 12 mice (four mice in each genotype), four
types of tissues (brown fat, skeletal, liver and heart) were applied to microarray experiment
separately to study the expression changes across genotypes. For duplicate spots, the mean
of the duplicates was used. Data from the four tissues were combined and log2 transformed.
Genes with little information content (average log2-scaled means ≤ 7 or average log2-scaled
standard deviations ≤ 0.4) are filtered out. A total of 4,288 genes are left for meta-analysis.
Among the 48 arrays performed, four arrays were identified with a quality defect and were
deleted from further analysis. The detailed sample information is described in Table 8.
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Table 9: Sample information of the mouse trauma data
set.
Array platform Codelink Affymetrix totalExperimental conditionsa I II III IV V I II III IV V
Number of arrays 4 3 4 4 4 4 3 4 4 4 38
aI:no manipulation; II: 1.5h HS; III: 1.5h HS+BF+1h R; IV:
1.5h HS+BF+4.5h R; V: 1.5h HS+BF+6h R.
The second data set applied is about mouse trauma experiments. Victims of trauma-
hemorrhagic shock (T-HS) (for example those due to car accident etc) often die due to severe,
complex and uncontrollable physiological disturbances that occur in many organs, especially
the liver. The progress of T-HS and resuscitation (R) is examined by well controlled murine
systems to identify gene expression profiles that are characteristic of this stress. Specifically
five groups of mice experiments were performed: (I) non-manipulated mice to serve as the
negative control group; (II) 1.5h of Hemorrhagic Shock without resuscitation (1.5hHS) served
as the positive control group; (III) 1.5h of hemorrhagic shock + bone fracture, followed by
one hour of fluid resuscitation (1.5hHS+BF+1hR); (IV) Similar to group III except for 4.5h
of fluid resuscitation (1.5hHS+BF+4.5hR); (V) Similar to group III except for 6h of fluid
resuscitation (1.5hHS+BF+6hR). Four mice are in each group with the liver samples applied
to microarray experiments (a total of 20 mice). The array experiments are done twice by
both Codelink and Affymetrix platforms. One array of group II in Codelink and one array
of group II in Affymetrix was of problematic quality and was removed from further analysis.
Table 9 describes the experimental details of the multi-platform data. After some standard
preprocessing procedures, 19,132 genes from Affymetrix platform and 26,063 genes from
Codelink platform were matched by GeneCruiser, resulting in 6,338 common genes for the
meta-analysis in this chapter.
The first data set contains a multi-tissue design. The application of HS1 helps to detect
tissue-specific biomarkers and HS2 identifies consistent tissue-invariant biomarkers. Both
hypothesis settings are of biological interest. On the other hand, the second data set contains
a multi-platform design. HS2 is of interest to generate highly confident biomarkers confirmed
by both platforms while HS1 becomes of less biological interest. The detected platform-
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specific biomarkers from HS1 may help to identify technical issues across the two platforms.
In general, we consider S studies to be combined (S = 4 in mouse metabolism data
and S = 2 in mouse trauma data). Among each study, K groups of samples are measured
with nsk replicates for study s and group k. Denote by xsgki the expression intensity of
gene g(1 ≤ g ≤ G), study s(1 ≤ s ≤ S), group k(1 ≤ k ≤ K) and replicated sample
i(1 ≤ i ≤ nsk). In this chapter, we particularly consider the situation when K > 2.
4.2.2 ANOVA-maxP for multiple studies
ANOVA-maxP is a natural extension of the traditional p-value based meta-analysis method.
The method is to take, for each gene, the maximum p- value observed over the S studies as
the test statistic. As a result, a biomarker is conservatively detected only if the p-values for
all studies are small. In the multi-class data structure considered in this chapter, the ANOVA
model is first used to test the significance of variation in gene expressions across phenotype
groups in each study. The corresponding p-values from the F-test are then combined by
taking the maximum (Box 1).
Box 1. Procedures for ANOVA-maxP
1. Compute the F-statistic, Fgs, for gene g in the sth study.
2. Permute group labels in each study for B times, and similarly calculated the permuted
statistics, F
(b)
gs , where 1 ≤ g ≤ G, 1 ≤ s ≤ S and 1 ≤ b ≤ B.







(B ·G) , where I(·) is the
indicator function that takes value one when the statement is true and zero otherwise.
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g′=1 I(Vg′ ≤ Vg))
.
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4.2.3 Multi-class correlation (MCC) for a pair of studies
Below we describe our proposed pairwise multi-class correlation measure (MCC), given a
gene, in two studies. For simplicity, we drop the subscript of gene g and studies s. Consider
xkj(1 ≤ k ≤ K, 1 ≤ j ≤ nk) to represent the expression intensity of class k, sample j for
the first study and xkj(1 ≤ k ≤ K, 1 ≤ j ≤ mk) for the second study. A naive measure
to quantify the correlation of the expression patterns across two studies may be the direct
sample correlation of (x11, . . . , x1n1 , . . . , xK1, . . . , xKnk) and (y11, . . . , y1m1 , . . . , yK1, . . . , yKmk)
if nk = mk, ∀k. However, since nk 6= mk in general and this naive definition ignores the
exchangeability within (x11, . . . , x1nk) and (y11, . . . , y1mk) for a given 1 ≤ k ≤ K, we need to
develop a better-defined correlation measure.
Assume we know the underlying distribution Xk and Yk, where xkj are i.i.d. from Xk,
ykj are i.i.d. from Yk, E(Xk) = µXk , E(Yk) = µYk , V ar(Xk) = σ
2
Xk




Also assume Xk’s and Yk’s are independent. Define a bivariate distribution (X, Y ) to be the
equal mixture of bivariate distributions (Xk, Yk) such that











where FX(·) represent the cumulative distribution function of X. We define the multi-class
correlation measure of (X1, . . . , XK) and (Y1, . . . , YK) to be cor(X, Y ). It can be easily shown
that
ρ((X1, . . . , XK), (Y1, . . . , YK))
=
E(XY )− EX · EY√







































k=1 µYk . This correlation measure takes values
between -1 and 1. A large positive correlation indicates a similar pattern between two
studies for a given gene.
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In practice, distributions of (Xk, Yk) are unknown. Instead we are given a set of observa-
tions (x˜, y˜), where x˜ = {xkj, 1 ≤ k ≤ K, 1 ≤ j ≤ nk},y˜ = {ykj, 1 ≤ k ≤ K, 1 ≤ j ≤ mk}. De-
note by X ′k the empirical distribution of {xkj, 1 ≤ j ≤ nk} such that FX′k =
∑nk
j=1 I(xkj ≤ t)
and similarly FY ′k =
∑nk
j=1 I(ykj ≤ t). Define (X ′, Y ′) to be an equal mixture of bivariate
distribution (X ′k, Y
′
k) such that











The multi-class correlation (MCC) based on the observed (x˜, y˜) becomes
ρ(x˜, y˜)
=
E(X ′Y ′)− EX ′ · EY ′√








































j=1(xkj − µX′k)2/nk and σ2Y ′k =∑nk
j=1(ykj − µY ′k)2/mk.
Detailed procedures for the application of MCC for finding biomarkers with consistent
patterns in two studies are listed in Box 2.
Box 2. Procedures of MCC for combining two studies
1. Compute MCC statistic, MCCg for given gene g.
2. Permute group labels in each study for B times, and similarly calculated the permuted
statistics, MCC
(b)
g , where 1 ≤ g ≤ G, 1 ≤ s ≤ S and 1 ≤ b ≤ B.






















4.2.4 Min-MCC for multiple studies
The MCC measure described above measures correlation between two given studies. It can
be extended for identifying genes with a consistent pattern across more than two studies. The
minimum MCC is defined as min −MCCg = min1≤u≤v≤S(MCCg(u)(v)), where MCCg(u)(v)
is the MCC measure for gene g and between study u and study v. With slight modification
of the algorithm in Box 2, the algorithm for min-MCC is provided in Box 3.
Box 3. Procedures of min-MCC for combining multiple studies
1. Compute the MCC statistic, MCCg(u)(v) for given gene g and for a pair of studies u
and v.
2. Permute group labels in each study for B times, and similarly calculated the permuted
statistics, MCC
(b)
g(u)(v) for study u and v, where 1 ≤ g ≤ G, 1 ≤ s ≤ S and 1 ≤ b ≤ B.









g′=1 I(min−MCC(b)g′ ≥ min−MCCg)
(B ·G) .





g′=1 I(min−MCC(b)g′ ≤ min−MCCg)
(B
∑G




We conducted two simulation scenarios for combining two and three genomic studies to
assess the performance of our proposed min-MCC method and ANOVA-maxP, where the
MCC method for combining two studies is a special case of min-MCC. Denote by xsgki the
expression intensity of study s(1 ≤ s ≤ S), gene g(1 ≤ g ≤ G), sample class k(1 ≤ k ≤ K)
and replicated sample i(1 ≤ i ≤ nsk). In the first simulation scenario, we simulated two
studies (S = 2) and the performance of MCC and ANOVA-maxP was compared. In the
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Table 10: Settings of the first simulation scenario.
Scenario 1
Effect size N Study 1 Study2(n11, n12, n13) = (10, 5, 8) (n21, n22, n23) = (5, 8, 10)

















I: genes with concordant patterns across studies. II: genes with discordant
patterns across studies. Null: null genes.
second scenario, three studies were simulated (S = 3) and we compared ANOVA-maxP
with min-MCC. Each study had three subclasses (K = 3). The numbers of replicates, nsk
(1 ≤ s ≤ S and 1 ≤ k ≤ K), were different among each subclass of each study. A total of
G=2000 genes in each study were simulated. Among these 2000 genes, 300 genes displayed
concordant patterns across all studies (category I) and 100 genes were discordant(category
II). The expression intensities were simulated from xsgki ∼ N(µsk, σ2s). For genes with
concordant pattern, mean vectors µs = (µs1, . . . , µsk) across studies had pair-wise correlation
one. For discordant genes, the pair-wise correlation of mean vectors was low or negative. For
the rest of the 1600 null genes, (µs1, . . . , µsk) = (0, . . . , 0). The effect size was defined as the
ratio of the standard deviation of the mean vectors to the within group standard deviation,
σs. We chose effect sizes to be 0.5, 0.6, 0.7 and 0.8. The false discovery rate (FDR) was
controlled at 0.05 for each method, and each simulation was repeated 200 times. The details
of the simulation settings are described in Tables 10 and 11.
The average number of genes identified in each category under the two different scenarios
are presented in Tables 12 and 13 respectively. As expected, the ANOVA-maxP detects both
category I and category II genes because the p-values in ANOVA do not reflect the pattern
information for each individual study. On the other hand, min-MCC method detects almost
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Table 11: Settings of the second simulation scenario.
Scenario 2
Effect size N Study 1 Study 2 Study 3(n11, n12, n13) = (10, 5, 8) (n21, n22, n23) = (5, 8, 10) (n31, n32, n33) = (8, 10, 5)
(µ11, µ12, µ13), σ1 (µ21, µ22, µ23), σ2 (µ31, µ32, µ33), σ3
0.5
I (1,3,5),3.5 (2,4,6),3.1 (1,4,7),4.4
II (1,3,5,3.5 (6,4,2),3.1 (1,7,4),5.3
III (0,0,0),3.5 (0,0,0),3.1 (0,0,0),4.4
0.6
I (1,3,5),2.9 (2,4,6),2.6 (1,4,7),3.7
II (1,3,5),2.9 (6,4,2),2.6 (1,7,4),4.4
Null (0,0,0),2.9 (0,0,0),2.6 (0,0,0),3.7
0.7
I (1,3,5),2.5 (2,4,6),2.2 (1,4,7),3.2
II (1,3,5),2.5 (6,4,2),2.2 (1,7,4),3.8
Null (0,0,0),2.5 (0,0,0),2.2 (0,0,0),3.2
0.8
I (1,3,5),2.2 (2,4,6),1.9 (1,4,7),2.8
II (1,3,5),2.2 (6,4,2),1.9 (1,7,4),3.3
Null (0,0,0),2.2 (0,0,0),1.9 (0,0,0),2.8
I: genes with concordant patterns across studies. II: genes with discordant patterns across studies.
Null: null genes.
only concordant genes (category I) and is much more powerful than the ANOVA-maxP if
the goal is to identify only concordant genes. For instance, when the effect size equals
0.6 and three studies are combined, min-MCC detects an average of 265.2 (out of 300)
genes of true concordant pattern genes, while ANOVA-maxP only identifies 206.1 together
with 67.7 discordant genes. If the biological goal is to identify only genes with concordant
patterns, min-MCC provides a better performance (false discovery rate should be calculated
as FDR1=(II+null)/(I+II+null) in this case). On the other hand, if genes with discordant
genes are also of biological interests, the ANOVA-maxP should be the method of choice (false
discovery rate calculated as FDR2 = (null)/(I + II + null)). We note that the simulation
results are all slightly conservative (true FDR ∼= 0.04 when nominal FDR is controlled
at 0.05). This is because the parameter pi0, the proportion of null genes, is set to equal 1
throughout all of the methods (Boxes 1-3). The estimation of pi0 has been a difficult issue
and it has been shown that improper estimation can lead to poor inference. To always set
pi0 = 1 can be conservative (i.e. few biomarkers are claimed as it should be). But in the
situation that most genes in the genome are non-differentially expressed, which is true in
many applications, the effect will be minimal.
47
Table 12: Evaluation of ANOVA-maxP and MCC methods by simulation in the first
scenario.
Effect size Methods I II Null FDR1 = II+NullI+II+Null FDR2 =
Null
I+II+Null
0.5 ANOVA-maxP 41.9 13.6 2.4 0.28 0.04 a
min-MCC 113.1 0.0 4.7 0.04 b 0.04
0.6 ANOVA-maxP 113.5 37.4 6.5 0.28 0.04 a
min-MCC 205.6 0.0 8.1 0.04 b 0.04
0.7 ANOVA-maxP 174.2 57.4 9.8 0.28 0.04 a
min-MCC 260.5 0.1 10.5 0.04 b 0.04
0.8 ANOVA-maxP 228.8 76.1 13.2 0.28 0.04 a
min-MCC 286.7 0.1 11.4 0.04 b 0.04
I: genes with concordant patterns across studies. II: genes with discordant patterns across
studies. Null: null genes.
aANOVA-maxP detects both concordant and discordant genes. FDR2 is a better measure for
false discoveries.
bMCC detects only concordant genes. FDR1 is a better measure for false discoveries.
Table 13: Evaluation of ANOVA-maxP and min-MCC methods by simulation in the
second scenario.
Effect size Methods I II Null FDR1 = II+NullI+II+Null FDR2 =
Null
I+II+Null
0.5 ANOVA-maxP 126.6 42.0 7.2 0.28 0.04 a
min-MCC 210.2 0.2 9.2 0.04 b 0.04
0.6 ANOVA-maxP 206.1 67.7 11.6 0.28 0.04 a
min-MCC 265.2 0.05 11.5 0.04 b 0.04
0.7 ANOVA-maxP 258.5 85.9 15.2 0.28 0.04 a
min-MCC 289.2 0.02 12. 0.04 b 0.04
0.8 ANOVA-maxP 286.0 95.0 15.9 0.28 0.04 a
min-MCC 297.6 0.0 12.8 0.04 b 0.04
I: genes with concordant patterns across studies. II: genes with discordant patterns across studies.
Null: null genes.
aANOVA-maxP detects both concordant and discordant genes. FDR2 is a better measure for false
discoveries.
bmin-MCC detects only concordant genes. FDR1 is a better measure for false discoveries.
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4.3.2 Application to mouse metabolism data
We applied both the ANOVA-maxP and the min-MCC methods to the mouse metabolism
data. The first biological goal was to identify biomarkers that have a consistent pattern across
all four tissues (i.e. reliable tissue-invariant biomarkers). To achieve this goal, the min-MCC
was better. A total of 394 genes were identified and are displayed in Figure 6A. It is clearly
seen that these genes have a clear concordant pattern across all four tissues. A simple cluster
analysis can further group them into six major patterns for further biological investigations.
For the second biological goal, we were also interested in genes with clear but discordant
patterns across tissues. These tissue-dependent biomarkers reflected tissue-specific biological
changes under VLCAD and LCAD mutations. The ANOVA-maxP identified 676 genes and
the heatmap of detected biomarkers is shown in Figure 6B. Figure 6C shows a histogram
of min-MCC (minimum of pair-wise multi-class correlation measure) of the 676 detected
biomarkers. Also 431 of the 676 genes (63.76%) had negative min-MCC (i.e. with discordant
pattern in at least a pair of tissues). Figure 6D shows a heatmap of these 431 discordant
genes and they are potential targets to identify tissue-specific regulators in the mutations. For
instance, Figure 5 shows the box-plots and patterns of two genes, Acsl5 and Scd1, among the
722 genes. Acsl5 is known to be involved in fatty acid degradation pathway. When VLCAD
or LCAD is knocked out, this gene is down-regulated in brown fat tissue, suggesting the loss
of degradation and metabolism activity of fatty acid. On the other hand, Scd1 is known
to help synthesize fatty acid. Its up-regulation in the liver tissue when VLCAD or LCAD
is deleted seems to suggest that the defect of metabolism in these mice has increased the
activity of fatty acid synthesis in liver.
4.3.3 Application to mouse trauma data
We similarly applied the ANOVA-maxP and the min-MCC to the mouse trauma data. We
note that the two studies to be combined were from two commercial platforms, Affymetrix
and Codelink. Ideally both array platforms measure identical samples and there should
not exist any discordant pattern biomarker. Combining the two data sets should increase
statistical power and detect more concordant pattern genes. Indeed, by controlling the FDR
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Figure 6: Application to mouse metabolism data. A: heatmap of 394 min-MCC genes, B:
heatmap of 676 ANOVA-maxP genes, C: histogram of min-MCC of the 676 ANOVA-maxP
genes, D: heatmap of 431 discordant ANOVA-maxP genes. (B: Brown fat; L: Liver; H:
Heart; S: Skeletal muscle. 1: Wild type; 2: VLCAD -/-; 3: LCAD -/-.).
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at 0.05, 4,004 genes were identified using the min-MCC (figure 7A). These highly-reliable
biomarkers confirmed by both platforms were used for further cluster analysis and pathway
analysis to understand the biological changes under different levels of severity of trauma
(manuscript in preparation). On the other hand, the ANOVA-maxP detected 3,587 genes
(heatmap shown in Figure 7B) and 208(5.8%) genes showed discordant patterns of negative
MCCs across the two platforms (Figure 7C). The higher proportion of genes with concordant
patterns confirmed that the two array platforms are highly reproducible. The 208 discordant
genes, however, need further investigation (heatmap in Figure 7D). The discordances are
possibly due to mistaken gene annotation, differential hybridization efficiencies caused by
different probe selection criteria or non-specific cross-hybridization.
4.4 DISCUSSION
Systematic information integration helps to increase the statistical power of biomarker detec-
tion. The evaluation of performance and choice of method depend on the ultimate biological
goal. Many meta-analysis methods have been proposed for combining two-class genomic
studies. In this chapter, we consider the issue of combining multi-class microarray studies.
Two methods are proposed and evaluated. The statistic ANOVA-maxP takes the maximum
of the ANOVA p-values in all studies. The method detects genes with clear class-wise pat-
terns (i.e. large between-class variation and small within-class variation). It is easily seen
that p-values of the ANOVA method cannot provide pattern information and genes detected
may have discordant patterns across studies. To identify concordant pattern biomarkers
across studies, we develop a novel multi-class correlation measure (MCC) via a bivariate
equal-weight mixture distribution from the observations of a pair of studies. The method is
extended to taking the minimum of the MCC of all pairwise studies (min-MCC) when more
than two studies are considered. We showed that the ANOVA-maxP and min-MCC are com-
plementary methods for combining multiple multi-class microarray studies depending on the
ultimate biological purposes. When study variations are expected and both study-invariant
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Figure 7: Application to mouse trauma data. A: heatmap of 4,004 min-MCC genes, B:
heatmap of 3,587 ANOVA-maxP genes, C: histogram of min-MCC of the 3,587 ANOVA-
maxP genes, D: heatmap of 208 discordant ANOVA-maxP genes.
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ests, the ANOVA-maxP performs well. When detecting highly reliable biomarkers (i.e. only
study-invariant or concordant pattern genes) is the goal, the min-MCC is a better choice
and provides better statistical power.
There are a few possible extensions and future directions. The two proposed methods
utilize the most conservative and extreme statistic (maximum of ANOVA p-values and min-
imum of pairwise MCC). This may be too stringent and sensitive to outliers especially when
K is large. A quick modification may be to use the rth ranked statistic instead.
Currently we consider all studies to have identical K classes. Both ANOVA-maxP and
min-MCC can be extended for studies containing mismatched and different number of classes.





With microarray technology becoming more prevalent in recent years, it is now common
for several laboratories to employ the same microarray technology to identify differentially
expressed genes that are related to the same phenomenon in the same species. Summarizing
information from multiple studies is becoming increasingly popular in this field. Meta-
analysis is an important component and often uses statistical methods to combine results
from a series of related studies. Increasing statistical power in detecting differentially ex-
pressed genes and confidence in inferences from individual studies are two major goals of
meta-analysis. The need of meta-analysis tools for combining microarray studies is obvious.
We develop a R package, genomeMeta, partly done in C which contains classes and
methods useful for analyzing and visualizing multiple microarray data sets. In genomeMeta,
we implement many of the tools described in previous chapters including the two statistics we
propose in chapter 3 and 4. Inputs are a list of microarray datasets with class information for
each dataset. genomeMeta produces meta-analysis results according to the different methods
and visualization of genes identified by the different methods.
This chapter provides an overview of how genomeMeta organizes data and describes the




We assume that as a first step all studies have been appropriately pre-processed and genes in
each study have been matched and merged by a common key (e.g. Unigene ID). We require
that the data object contains two lists. The first is a list of datasets from multiple studies.
Each dataset is a matrix with rows representing genes or variables, and columns representing
arrays or samples. The second is also a list which contains labels for each dataset. Each
label is an object of class “factor”.
5.2.2 genomeMeta methods
In genomeMeta, we implement many of the tools described in Chapters 2, 3 and 4. We
provide methods for the combination of datasets based on both two sample comparisons
and multiple-class comparisons. The available methods are shown in Figure 8. If each
study contains two classes, the traditional two-sample t statistic with unequal variance or
the moderated t statistic described in chapter 3 can be performed. The p-values are then
computed by permutation. For combining p-values, four methods are available to choose
from minP, maxP, Fisher and OW. As discussed and compared in previous chapters, maxP
aims to identify genes differentially expressed in all studies. The others methods aim to
identify genes differentially expressed in at least one of the studies. OW further divides
genes into several categories showing those in which study the gene is significant. minP is
not recommended for its poor power and unstable performance in general as shown in chapter
3. If a study has more than two classes, the F statistic with either equal or unequal variances
in analysis of variance is performed. Similarly, the p-values of the observed F statistics are
calculated from permutation. The p-values are then combined in the same manner.
Finally, genes with consistent patterns in all studies might be of more interest to re-
searchers. We provide a powerful method min-MCC which is derived based on an equal














Test for individual 
study
Combined methods
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Figure 8: The methods implemented in genomeMeta package.
5.3 EXAMPLE
Following the example for the GeneMeta package, we split the breast tumor study reported
by West et al. (2001) into two artificial studies and combine results from the two studies
using different methods. As expected, according to the quantile-quantile plot of the observed
vs. expected Cochran’s Q values (Gentleman et al. (2008)), the two datasets are homoge-
neous. We fit the moderated-t+OW and moderated-t+Fisher methods to the artificial split.
A plot of genes whose intensity levels are standardized within study is provided by the func-
tion plot.Metagene. If we are more interested in the number of genes that are below a given
threshold for the FDR we can use plot.fdr.
> dt < −list(data = list(d1, d2), label = list(l1, l2))
> library(genomeMeta)
> modt.ow < −genomeMeta(dt, nperm = 100, test =′ modt′,meta.method =′ OW ′)
> plot.fdr(modt.ow)
> plot.Metagene(modt.ow, fdr.cut = 0.05)
> modt.maxp < −genomeMeta(dt, nperm = 100, test =′ modt′,meta.method =′ Fisher′)
> plot.fdr(modt.maxp)
> plot.Metagene(modt.maxp, fdr.cut = 0.05)
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The second example is the mouse energy metabolism data. We apply both the ANOVA-
maxP and the min-MCC methods to the data. Plots are shown in Figure 10.
> dt < −list(data = list(brown, liver, heart, skeletal),
label = list(colnames(brown), colnames(liver), colnames(heart), colnames(skeletal)))
> library(genomeMeta)
> F.maxp < −genomeMeta(dt, nperm = 100, test =′ F ′,meta.method =′ maxP ′)
> plot.fdr(F.maxp)
> plot.Metagene(F.maxp, fdr.cut = 0.05)
> minmcc < −genomeMeta(dt, nperm = 100,meta.method =′ minMCC ′)
> plot.fdr(minmcc)
> plot.Metagene(minmcc, fdr.cut = 0.05)
With 200 permutations and 2000 genes, the analysis takes approximately within one
minute.
5.4 DISCUSSION
genomeMeta provides methods for analysis of multiple microarray studies. We organize the
data and output in an object that can be queried for individual analysis results, combined
analysis results and visualization of significant genes. More extensions are under way which
include the min-MCC methods dealing with studies containing mismatched and different
numbers of classes and other meta analysis methods as described in section 3 of chapter 2.
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Figure 9: Genes identified using Meta-analysis for breast tumor studies. A. moderated t +
OW method. Genes identified by OW with FDR ≤ 0.05. OW classifies genes into several
categories. B. moderated t + OWmethod. The number of genes that are below the threshold
for FDR. C. moderated t + Fisher method. Genes identified by OW with FDR ≤ 0.05. D.
moderated t + Fisher method. The number of genes that are below the threshold for FDR.
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Figure 10: The heatmaps of genes identified using Meta-analysis for mouse energy
metabolism studies. A. F + maxP method. F+maxP identifies genes (FDR ≤ 0.05) whose
expressions significantly vary across genotypes in all tissues. B. F + maxP method. The
number of genes that are below the threshold for FDR. C. min-MCC method. Only genes
with consistent variation across genotypes in all tissues are detected (FDR ≤ 0.05). D.
min-MCC method. The number of genes that are below the threshold for FDR.
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6.0 CONCLUSION
Large-scale meta-analysis of genomic studies is becoming increasingly common, because it is
now more feasible and there are a greater volume of data sets available. In this dissertation,
I have addressed these issues as follows:
In Chapter 3, I clarified that some existing meta-analytic methods are for different bi-
ological purposes. The need to distinguish them is more obvious in genomic studies. Two
complementary hypothesis settings are outlined. And all meta-analytic methods targeted
for their respective hypothesis settings are clarified. Focusing on one of the hypotheses, we
proposed a new meta-analytic method to facilitate combination of similar microarray studies.
This method is named as the optimally-weighted statistic, which is based on the weighting
scheme of the famous Fisher’s method. The statistic is constructed as the minimum of the
p-values of the weighted Fisher’s statistic for all possible weights. We have shown that this
method is admissible under Birnbaum’s theorem. By comparing it with other popular meth-
ods, we showed that it had better power for detecting genes differentially expressed in part
of the data sets with a tradeoff of slightly lesser power than Fisher’s method in detected
genes differentially expressed in all data sets. In general our method is powerful and supe-
rior to the others. Moreover, the optimal weights of each study for each gene produced by
the method can lead to further categorization of differentially expressed genes, showing in
which studies the identified genes are differentially expressed. The application to the multi-
tissue mouse energy metabolism study and multiple prostate cancer studies have shown that
the optimally-weighted statistic is very well suited to the setting where we expect tests to
vary across data sets. We conducted extensive simulations to assess the performance of our
proposed method and some existing methods with regard to the number of genes detected
in different settings and the estimate of the false discovery rate under different scenarios.
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Optimally-weighted method is more robust to varying scenarios.
In contrast to the combining estimates approach, the optimally-weighted method com-
bines p-values. The principal objection to the combining p-value approaches is failure in
producing direction and magnitude. However, data structures and statistical hypotheses
in multiple microarray studies may differ, making a direct combination of estimates inap-
propriate. Moreover, there are two ways to incorporate direction information for a p-value
based method. One is to incorporate signs according to the effect estimates, the other is to
consider a one-sided p-value. We utilized the first way to further filter out identified genes
with inconsistent regulations across data sets. However, this strategy is not feasible where
there are multiple classes in each study.
To deal with studies with more than two classes, we proposed two methods in chapter 4.
The first is a natural extension of Wilkinson’s maximum p-value method. The ANOVAmodel
is first used to test the significance of variation in gene expressions across multiple classes
in each study. The corresponding p-values from the F-test are then combined by taking the
maximum. This approach is denoted as the ANOVA-maxP. Obviously, the ANOVA-maxP
identifies genes significantly vary across classes in all studies. It is unable to filter genes that
differ in any pattern between classes across studies. Here, we proposed a second test statistic,
the multi-class correlation statistic (MCC), based on an equal mixture of bivariate normal
distributions. We assume that the gene expressions from the same class of two studies follow
a bivariate distribution. We further assume that there is an equal probability of sampling
each class. This assumption allows us to conveniently construct a statistic to assess the
correlation between two studies. Moreover, a large positive MCC indicates a similar pat-
tern between two studies. It also overcomes the infeasibility of Pearson’s correlation when
the studies have unequal sample sizes. The MCC measure is further extended to identify
genes with a consistent pattern across more than two studies. We considered minimizing
all pairwise multi-class correlations of all studies (min-MCC). The min-MCC was compared
with the ANOVA-maxP in a simulation study and in applications to multi-tissue mouse en-
ergy metabolism and mouse trauma data sets. In the simulation, the min-MCC shows much
higher power in identifying genes with consistent patterns across studies than ANOVA-maxP.
It is not surprising that the ANOVA-maxP also identifies plenty of genes with inconsistent
61
patterns across studies. Both methods have been shown to be indispensable in the appli-
cations, and the min-MCC helps to detect genes have same pattern across studies. On the
other hand, genes that are differentially expressed with different patterns across studies are
also of interest to researchers. In this case, the combination of the ANOVA-maxP and the
min-MCC can be implemented.
There are a few possible extensions and future directions. The two proposed methods
utilize the most conservative and extreme statistic (maximum of ANOVA p-values and min-
imum of pairwise MCC). This may be too stringent and sensitive to outliers especially when
K is large. A quick modification may be to use the rth ranked statistic instead. Currently we
consider all studies to have identical K classes. Both the ANOVA-maxP and the min-MCC
can be extended for studies containing mismatched and different number of classes. For the
min-MCC, the pairwise MCC can be defined using only the overlapping classes across a pair
of studies.
In applications, we only consider matched genes from all studies. In practice, studies to be
combined usually come from different microarray platforms. Genes that are missing in part
of the studies are not considered. As the number of studies increases, much fewer genes can
be matched. An extension allowing non-matched genes is necessary. This dissertation only
considered integrative analysis of microarray data sets, the statistical methods we proposed
are flexible and can be easily applied to other similar data sets such as SNP arrays, genome
arrays, methylation arrays, proteomic experiments and ChIP-on-chip experiments.
In the end, we developed a R package - genomeMeta which implemented the statistical
tools we described in this dissertation. More extensions as we described above are under
process.
This work attempts to improve the identification of biologically meaningful genes and
could improve significant findings by providing more accurate answers and providing a brand
new direction to a rarely discussed statistical issue yet important in practice.
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